Dianthus Therapeutics, Inc. /DE/ Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff · last filed 2026-03-09
- Dianthus Therapeutics, Inc. /DE/ debt securities, available-for-sale, allowance for credit loss, writeoff for the quarter ending 2024-12-31 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ debt securities, available-for-sale, allowance for credit loss, writeoff for the quarter ending 2024-09-30 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ debt securities, available-for-sale, allowance for credit loss, writeoff for the quarter ending 2024-06-30 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ debt securities, available-for-sale, allowance for credit loss, writeoff for the quarter ending 2024-03-31 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ debt securities, available-for-sale, allowance for credit loss, writeoff for fiscal 2025 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ debt securities, available-for-sale, allowance for credit loss, writeoff for fiscal 2024 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ debt securities, available-for-sale, allowance for credit loss, writeoff for fiscal 2023 was $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff 3 month | Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff 6 month | Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff 9 month | Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2024-08-08 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |